Loading data for MBRX — first visit, this takes a few seconds.
Moleculin Biotech, Inc. (MBRX)
NasdaqCM: MBRX
· 即時價格 · USD
0.82
+0.05 (6.49%)
收盤價： Sep 11, 2026, 3:59 PM
0.73
+2.60%
盤後: 7:25 PM
股價、關鍵數字和最新消息，都在這一頁。
Moleculin Biotech, Inc.（MBRX）股價、分析與資料
7.71% (1D)
| 買價 | 0.57 |
| 市值 | 13.9M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -32.5M |
| 1.92 | |
| 14.59 | |
| 0.05 | |
| -0.01 | |
| P/B (ttm) | 0.44 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 1.07 |
| 成交量 | 351,460 |
| 20 日平均成交量 | 1,284,117 |
| 開盤價 | 0.79 |
| 前收盤價 | 0.77 |
| 當日區間 | 0.77 - 0.83 |
| 52 週範圍 | 0.16 - 15.75 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 MBRX
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, whic...
完整的公司簡介財報驚奇
Moleculin Biotech 已於 Aug 13, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -1.4 超出預期 0.15, 年增 91.88% 成長.
